Analyst firms · Barclays · HUM

Barclays HUM price target and rating history

Humana Inc. (HUM) · Health Care

Barclays rates Humana Inc. (HUM) Overweight with a $515 price target, as of its latest action on Sep 25, 2026. It has published 5 rating actions on HUM since September 2021, including 1 upgrade and 0 downgrades. Across 12 firms with a HUM price target in the last 12 months, the median target is $501. Barclays's $515 is 3% above that.

Current rating
Overweight
Price target
$515
Median target, all firms
$501
Actions on HUM
5

Barclays price target on HUM

$540$448$35620222023202420252026
Barclays price target on HUM, each point a stated target, September 2021 to September 2026.

Every Barclays rating on HUM

How other firms rate HUM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
RBC Capital MarketsOutperform$563Nov 16, 2026
Raymond JamesOutperform$520Oct 12, 2026
Robert W. BairdOutperform$596Oct 9, 2026
Cantor FitzgeraldOverweight$460Oct 7, 2026
BarclaysOverweight$515Sep 25, 2026
Morgan StanleyEqual-Weight$370Aug 5, 2026
Evercore ISIOutperform$480Jul 30, 2026
Leerink PartnersOutperform$513Jul 30, 2026
BofA SecuritiesBuy$500Jul 29, 2026
Wells FargoOverweight$502Jul 13, 2026
Deutsche BankBuy$441May 20, 2026
JefferiesBuy$313Dec 5, 2025

Questions about Barclays and HUM

What is Barclays's price target for HUM?
Barclays's latest stated price target for Humana Inc. (HUM) is $515, from its action on Sep 25, 2026.
What is Barclays's rating on HUM?
Barclays rates HUM Overweight, a bullish rating, as of Sep 25, 2026.
When did Barclays last change its view on HUM?
On Sep 25, 2026, Barclays upgrades to Overweight from Equal Weight, price target $515.
How does Barclays's HUM target compare with other analysts?
Across 12 firms with a HUM price target in the last 12 months, the median target is $501. Barclays's $515 is 3% above that.

More HUM rating histories

All Barclays ratingsHUM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.